Shares of Peregrine Pharmaceuticals Inc. spiked 21 percent after the Tustin, Calif.-based firm reported a 50 percent improvement in overall response rate (ORR) in a Phase II study testing bavituximab in non-small-cell lung cancer (NSLCL).